You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)與諾華簽訂獨家授權協議
阿思達克 12-21 04:06
百濟神州(06160.HK)公布,與諾華(Novartis Pharma AG)簽署選擇權、合作和授權協議。據此,公司向諾華製藥授予一項獨家的、基於時間的選擇權,以獲得在授權區域(包括美國、加拿大、墨西哥、歐盟成員國、英國、俄羅斯和日本等)對公司在研TIGIT抑制劑ociperlimab進行開發、生產和商業化的獨家許可。 根據協議,公司將獲得3億美元的現金首付款,並有權在諾華行使的選擇權額外獨得6億或7億美元付javascript:goTo(109);款。同時,獲得最多7.45億美元監管里程碑付款、最多11.5億美元銷售里程碑付款,以及在授權區域年度淨銷售額近20%-25%佔比的分級特許使用費。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account